Cargando…

Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics

Congenital heart disease (CHD) is the most common birth defect. The prenatal diagnosis of fetal CHD is completely dependent on ultrasound testing, but only ~40% of CHD can be detected. The purpose of this study is to find good biomarkers in amniotic fluid (AF) to detect CHD in the second trimester,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yahong, Sun, Yun, Yang, Lan, Huang, Mingtao, Zhang, Xiaojuan, Wang, Xin, Guan, Xianwei, Yang, Peiying, Wang, Yan, Meng, Lulu, Zhou, Ran, Zhou, Xiaoyan, Luo, Chunyu, Hu, Ping, Jiang, Tao, Xu, Zhengfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215886/
https://www.ncbi.nlm.nih.gov/pubmed/34164441
http://dx.doi.org/10.3389/fcvm.2021.671191
_version_ 1783710325411938304
author Li, Yahong
Sun, Yun
Yang, Lan
Huang, Mingtao
Zhang, Xiaojuan
Wang, Xin
Guan, Xianwei
Yang, Peiying
Wang, Yan
Meng, Lulu
Zhou, Ran
Zhou, Xiaoyan
Luo, Chunyu
Hu, Ping
Jiang, Tao
Xu, Zhengfeng
author_facet Li, Yahong
Sun, Yun
Yang, Lan
Huang, Mingtao
Zhang, Xiaojuan
Wang, Xin
Guan, Xianwei
Yang, Peiying
Wang, Yan
Meng, Lulu
Zhou, Ran
Zhou, Xiaoyan
Luo, Chunyu
Hu, Ping
Jiang, Tao
Xu, Zhengfeng
author_sort Li, Yahong
collection PubMed
description Congenital heart disease (CHD) is the most common birth defect. The prenatal diagnosis of fetal CHD is completely dependent on ultrasound testing, but only ~40% of CHD can be detected. The purpose of this study is to find good biomarkers in amniotic fluid (AF) to detect CHD in the second trimester, so as to better manage this group of people and reduce the harm of CHD to the fetus. Metabolites analysis were performed in two separate sets. The discovery set consisted of 18 CHD fetal maternal AF samples and 35 control samples, and the validation set consisted of 53 CHD fetal maternal AF samples and 114 control samples. Untargeted metabolite profiles were analyzed by gas chromatography/time-of-flight-mass spectrometry (GC-TOF/MS). Orthogonal partial least square discrimination analysis (OPLS-DA) demonstrated that CHD and control samples had significantly different metabolic profiles. Two metabolites, uric acid and proline, were significantly elevated in CHD and verified in two data sets. Uric acid was associated with CHD [odds ratio (OR): 7.69 (95% CI: 1.18–50.13) in the discovery set and 3.24 (95% CI:1.62–6.48) in the validation set]. Additionally, uric acid showed moderate predictive power; the area under curve (AUC) was 0.890 in the discovery set and 0.741 in the validation set. The sensitivity and specificity of uric acid to detect CHD was, respectively, 94.4 and 74.3% in the discovery set and 67.9 and 71.9% in the validation set. The identification of uric acid as a biomarker for CHD has the potential to stimulate research on the pathological mechanism of CHD and the development of a diagnostic test for clinical applications.
format Online
Article
Text
id pubmed-8215886
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82158862021-06-22 Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics Li, Yahong Sun, Yun Yang, Lan Huang, Mingtao Zhang, Xiaojuan Wang, Xin Guan, Xianwei Yang, Peiying Wang, Yan Meng, Lulu Zhou, Ran Zhou, Xiaoyan Luo, Chunyu Hu, Ping Jiang, Tao Xu, Zhengfeng Front Cardiovasc Med Cardiovascular Medicine Congenital heart disease (CHD) is the most common birth defect. The prenatal diagnosis of fetal CHD is completely dependent on ultrasound testing, but only ~40% of CHD can be detected. The purpose of this study is to find good biomarkers in amniotic fluid (AF) to detect CHD in the second trimester, so as to better manage this group of people and reduce the harm of CHD to the fetus. Metabolites analysis were performed in two separate sets. The discovery set consisted of 18 CHD fetal maternal AF samples and 35 control samples, and the validation set consisted of 53 CHD fetal maternal AF samples and 114 control samples. Untargeted metabolite profiles were analyzed by gas chromatography/time-of-flight-mass spectrometry (GC-TOF/MS). Orthogonal partial least square discrimination analysis (OPLS-DA) demonstrated that CHD and control samples had significantly different metabolic profiles. Two metabolites, uric acid and proline, were significantly elevated in CHD and verified in two data sets. Uric acid was associated with CHD [odds ratio (OR): 7.69 (95% CI: 1.18–50.13) in the discovery set and 3.24 (95% CI:1.62–6.48) in the validation set]. Additionally, uric acid showed moderate predictive power; the area under curve (AUC) was 0.890 in the discovery set and 0.741 in the validation set. The sensitivity and specificity of uric acid to detect CHD was, respectively, 94.4 and 74.3% in the discovery set and 67.9 and 71.9% in the validation set. The identification of uric acid as a biomarker for CHD has the potential to stimulate research on the pathological mechanism of CHD and the development of a diagnostic test for clinical applications. Frontiers Media S.A. 2021-06-07 /pmc/articles/PMC8215886/ /pubmed/34164441 http://dx.doi.org/10.3389/fcvm.2021.671191 Text en Copyright © 2021 Li, Sun, Yang, Huang, Zhang, Wang, Guan, Yang, Wang, Meng, Zhou, Zhou, Luo, Hu, Jiang and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Li, Yahong
Sun, Yun
Yang, Lan
Huang, Mingtao
Zhang, Xiaojuan
Wang, Xin
Guan, Xianwei
Yang, Peiying
Wang, Yan
Meng, Lulu
Zhou, Ran
Zhou, Xiaoyan
Luo, Chunyu
Hu, Ping
Jiang, Tao
Xu, Zhengfeng
Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics
title Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics
title_full Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics
title_fullStr Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics
title_full_unstemmed Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics
title_short Analysis of Biomarkers for Congenital Heart Disease Based on Maternal Amniotic Fluid Metabolomics
title_sort analysis of biomarkers for congenital heart disease based on maternal amniotic fluid metabolomics
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215886/
https://www.ncbi.nlm.nih.gov/pubmed/34164441
http://dx.doi.org/10.3389/fcvm.2021.671191
work_keys_str_mv AT liyahong analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT sunyun analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT yanglan analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT huangmingtao analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT zhangxiaojuan analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT wangxin analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT guanxianwei analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT yangpeiying analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT wangyan analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT menglulu analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT zhouran analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT zhouxiaoyan analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT luochunyu analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT huping analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT jiangtao analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics
AT xuzhengfeng analysisofbiomarkersforcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomics